This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisseha, M. Articles by Zollinger, W. Search for Related Content PubMed PubMed Citation Articles by Fisseha, M. Articles by Zollinger, W.

 Previous Article  |  Next Article 

Infection and Immunity, July 2005, p. 4070-4080, Vol. 73, No. 7
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.7.4070-4080.2005

Characterization of Native Outer Membrane Vesicles from lpxL Mutant Strains of Neisseria meningitidis for Use in Parenteral Vaccination

Makda Fisseha, Ping Chen, Brenda Brandt, Todd Kijek, Elizabeth Moran, and Wendell Zollinger^*

The Walter Reed Army Institute of Research, Silver Spring, Maryland

Received 20 December 2004/ Returned for modification 25 January 2005/ Accepted 20 February 2005

Native outer membrane vesicles (NOMV) of Neisseria meningitidis consist of intact outer membrane and contain outer membrane proteins (OMP) and lipooligosaccharides (LOS) in their natural conformation and membrane environment. NOMV have been safely used intranasally in P1 studies with encouraging results, but they are too toxic for parenteral vaccination. We now report the preparation and characterization of lpxL mutants that express LOS with reduced toxicity, and the evaluation of the potential of NOMV from these strains for use as a parenteral vaccine. A series of deletion mutants were prepared with knockouts of one or more of the lpxL1, lpxL2, or synX genes. The lpxL2 mutants had a reduced growth rate, reduced level of LOS expression, and increased sensitivity to surfactants. In addition, synX lpxL2 double mutants had reduced viability in stationary phase. The lpxL1 lpxL2 double mutant behaved essentially the same as the lpxL2 single mutant. LOS from both lpxL mutant strains exhibited altered migration on polyacrylamide gels. The LOS of lpxL2 mutants of L3,7 strains were fully sialylated. NOMV prepared from lpxL2 mutants was about 200-fold less active than wild-type NOMV in rabbit pyrogen tests and in tumor necrosis factor alpha release assays. Bactericidal titers induced in animals by lpxL2 mutant NOMV were lower than those induced by lpxL1 or wild-type NOMV. However, immunogenicity could be largely restored by use of an adjuvant. These results provide evidence that NOMV from lpxL2 mutant strains will be safe and immunogenic in humans when given parenterally.

Editor: D. L. Burns

Present address: Nestlé Research Center, Lausanne, Switzerland.

Present address: Sequella, Inc., Rockville, Maryland.

Present address: U.S. Army 121 General Hospital, Seoul, South Korea.

This article has been cited by other articles:

• Steeghs, L., Keestra, A. M., van Mourik, A., Uronen-Hansson, H., van der Ley, P., Callard, R., Klein, N., van Putten, J. P. M. (2008). Differential Activation of Human and Mouse Toll-Like Receptor 4 by the Adjuvant Candidate LpxL1 of Neisseria meningitidis. Infect. Immun. 76: 3801-3807 [Abstract] [Full Text]  
• Zhu, W., Thomas, C. E., Chen, C.-j., Van Dam, C. N., Johnston, R. E., Davis, N. L., Sparling, P. F. (2005). Comparison of Immune Responses to Gonococcal PorB Delivered as Outer Membrane Vesicles, Recombinant Protein, or Venezuelan Equine Encephalitis Virus Replicon Particles. Infect. Immun. 73: 7558-7568 [Abstract] [Full Text]